


# RSC Medicinal Chemistry

rsc.li/medchem

The Royal Society of Chemistry is the world's leading chemistry community. Through our high impact journals and publications we connect the world with the chemical sciences and invest the profits back into the chemistry community.

## IN THIS ISSUE

ISSN 2632-8682 CODEN RMCSCX 14(8) 1391-1582 (2023)



### Cover

See Robert W. Huigens III et al., pp. 1472–1481.  
Image reproduced by permission of Robert W. Huigens III from *RSC Med. Chem.*, 2023, **14**, 1472.  
Image credit: Authors of molecular image are Jing Bai, Jun Yang, Yong Zhou and Qing Yang. RCSB PDB: 3X22.

## EDITORIAL

1398

### Introduction to the themed collection on antimicrobial resistance

Jayanta Haldar, Sylvie Garneau-Tsodikova\* and Micha Fridman




## REVIEWS

1400

### Progress in the discovery and development of small molecule methuosis inducers

Tao Ye, Peipei Shan\* and Hua Zhang\*



## Editorial Staff

### Executive Editor

Rebecca Garton

### Deputy Editor

Jack Washington

### Editorial Production Manager

Sarah Whitehouse

### Development Editor

Emily Cuffin-Munday

### Publishing Editors

Nicola Burton, Tom Cozens, Katie Fernandez, Ryan Kean, Roxane Owen, Alex Rowles

### Editorial Assistant

Amy Cook

### Publishing Assistant

Andrea Whiteside

### Publisher

Sam Keltie

For queries about submitted papers, please contact Sarah Whitehouse, Editorial Production Manager, in the first instance. E-mail [medchem@rsc.org](mailto:medchem@rsc.org)

For pre-submission queries please contact Rebecca Garton, Executive Editor. E-mail [medchem-rsc@rsc.org](mailto:medchem-rsc@rsc.org)

RSC Medicinal Chemistry (electronic: ISSN 2632-8682) is published 12 times a year by the Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, UK CB4 0WF.

All orders, with cheques made payable to the Royal Society of Chemistry, should be sent to the Royal Society of Chemistry Order Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Tel +44 (0)1223 432398; E-mail [orders@rsc.org](mailto:orders@rsc.org)

2023 Annual (electronic) subscription price: £1643; US\$2435.

Customers in Canada will be subject to a surcharge to cover GST. Customers in the EU subscribing to the electronic version only will be charged VAT.

If you take an institutional subscription to any Royal Society of Chemistry journal you are entitled to free, site-wide web access to that journal. You can arrange access via Internet Protocol (IP) address at [www.rsc.org/ip](http://www.rsc.org/ip)

Customers should make payments by cheque in sterling payable on a UK clearing bank or in US dollars payable on a US clearing bank.

Whilst this material has been produced with all due care, the Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by the Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of the Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material. The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 207 4378 6556.

### Advertisement sales:

Tel +44 (0) 1223 432246; Fax +44 (0) 1223 426017;

E-mail [advertising@rsc.org](mailto:advertising@rsc.org)

For marketing opportunities relating to this journal, contact [marketing@rsc.org](mailto:marketing@rsc.org)

# RSC Medicinal Chemistry

[rsc.li/medchem](http://rsc.li/medchem)

*RSC Medicinal Chemistry* publishes significant research and review articles in medicinal chemistry and related drug discovery science.

## Editorial Board

### Editor-in-Chief

Mike Waring, Newcastle University, UK

### Associate Editors

Cynthia Dowd, George Washington University, USA

Maria Duca, Université Côte d'Azur - CNRS, France

Sally-Ann Poulsen, Griffith University, Queensland, Australia

Jian Zhang, Shanghai Jiao Tong University School of Medicine, China

### Members

Hayley Binch, Hoffmann-La Roche, Switzerland

Paola Castaldi, LifeMine Therapeutics, USA  
Matthew Fuchter, Imperial College London, UK

Lyn Jones, Dana-Farber Cancer Institute, Boston, USA

Jean-Louis Reymond, University of Bern, Switzerland

## Advisory Board

Timor Baasov, Israel Institute of Technology, Israel

Andreas Bender, University of Cambridge, UK  
Julian Blagg, Institute of Cancer Research, Sutton, UK

Margaret Brimble, University of Auckland, New Zealand

Mark Bunnage, Vertex Pharmaceuticals, USA  
Christopher Burns, Certara Therapeutics, Australia

Andrea Cavalli, University of Bologna, Italy  
Young-Tae Chang, POSTECH, South Korea

James Crawford, Genentech, Inc., USA  
Matthew Duncton, Rigel Pharmaceuticals Inc, San Francisco, USA

Stephen Frye, University of North Carolina at Chapel Hill, USA

Sylvie Garneau-Tsodikova, University of Kentucky, USA

Barry Gold, University of Pittsburgh, USA  
Jayanta Haldar, Jawaharlal Nehru Centre for Advanced Scientific Research, India

Gyoonhee Han, Yonsei University, Korea  
Mike Hann, GSK Medicine Research Centre, UK

Christian Heinis, EPFL, Switzerland  
Laura H. Heitman, Leiden University, Netherlands

Yoshinori Ikeura, Axcelad Drug Discovery Partners, Japan  
Ahmed Kamal, NIPER, Hyderabad, India

Bob (Robert) Langer, MIT, USA  
Steven V. Ley, University of Cambridge, UK

María Luz López Rodríguez, Complutense University of Madrid, Spain

Christa Müller, University of Bonn, Germany  
Roberto Pellicciari, University of Perugia, Italy  
David Rees, Astex Therapeutics, Cambridge, UK

Motonari Uesugi, Kyoto University, Japan  
John C. Vederas, University of Alberta, Canada  
Paul Wender, Stanford University, USA

Zhen Yang, Peking University, China  
Ming-Qiang Zhang, Amgen, Shanghai, China

## Information for Authors

Full details on how to submit material for publication in RSC Medicinal Chemistry are given in the Instructions for Authors (available from <http://www.rsc.org/authors>). Submissions should be made via the journal's homepage: [rsc.li/medchem](http://rsc.li/medchem)

Authors may reproduce/republish portions of their published contribution without seeking permission from the Royal Society of Chemistry, provided that any such republication is accompanied by an acknowledgement in the form: (Original Citation)–Reproduced by permission of the Royal Society of Chemistry.

This journal is © The Royal Society of Chemistry 2023.

Apart from fair dealing for the purposes of research or private study for non-commercial purposes, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulation 2003, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the Publishers or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. US copyright law is applicable to users in the USA.

Registered Charity No. 207890.




## REVIEWS

1410

## Dual functional therapeutics: mitigating bacterial infection and associated inflammation


Yash Acharya, Kashish Kumar Taneja and Jayanta Halder\*



1429

## Recent advancements in pharmacological strategies to modulate energy balance for combating obesity


Benudhara Pati, Satyabrata Sendh, Bijayashree Sahu, Sunil Pani, Nivedita Jena and Naresh Chandra Bal\*



1446

## Antibacterial activities of anthraquinones: structure–activity relationships and action mechanisms

Tang Qun, Tiantian Zhou, Jiongkai Hao, Chunmei Wang, Keyu Zhang, Jing Xu, Xiaoyang Wang\* and Wen Zhou\*




## RESEARCH ARTICLES


1472

## Design, synthesis and evaluation of halogenated phenazine antibacterial prodrugs targeting nitroreductase enzymes for activation

Ke Liu, Tao Xiao, Hongfen Yang, Manyun Chen, Qiwen Gao, Beau R. Brummel, Yousong Ding and Robert W. Huigens III\*




1482



### Inhibition of transcription and antiproliferative effects in a cancer cell line using antigene oligonucleotides containing artificial nucleoside analogues

Lei Wang, Ryotaro Notomi, Shigeki Sasaki and Yosuke Taniguchi\*


1492



### The sulfonadyns: a class of aryl sulfonamides inhibiting dynamin I GTPase and clathrin mediated endocytosis are anti-seizure in animal models

Luke R. Odell, Nigel C. Jones, Ngoc Chau, Mark J. Robertson, Joseph I. Ambrus, Fiona M. Deane, Kelly A. Young, Ainslie Whiting, Jing Xue, Kate Prichard, James A. Daniel, Nick N. Gorgani, Terence J. O'Brien, Phillip J. Robinson\* and Adam McCluskey\*


1512



### Discovery of imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents in streptozotocin-induced diabetes in Wistar rats *via* inhibition of DPP-4

Akanksha Gupta, Hans Raj Bhat and Udaya Pratap Singh\*

1537



### Bioorthogonal activation of prodrugs, for the potential treatment of breast cancer, using the Staudinger reaction

Madonna M. A. Mitry, Samuel Y. Boateng, Francesca Greco\* and Helen M. I. Osborn\*




## RESEARCH ARTICLES

1549

## Design, synthesis and biological evaluation of phenanthridine amide and 1,2,3-triazole analogues against *Mycobacterium tuberculosis*


Adinarayana Nandikolla, Yogesh Mahadu Khetmalis, Boddupalli Venkata Siva Kumar, Ala Chandu, Banoth Karan Kumar, Gauri Shetye, Rui Ma, Sankaranarayanan Murugesan, Scott G. Franzblau and Kondapalli Venkata Gowri Chandra Sekhar\*



1562

## Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability *in vitro* and *in vivo*

Yonghui Sun, Zimo Yang, Zhimin Zhang, Zhen Li, Liubin Guo, Hao Pan, Xin Luo, Dongzhou Liu\* and Yu Rao\*




Novel BTK degrader (15-271) with better bioavailability (F%)

- 💡 Optimized Structure with Fewer Rotatable Bonds
- 💡 Improved Solubility and Simple Synthetic Route
- 💡 Better Microsome Stability and Bioavailability *in vivo*

1567

## N-Acylsulfonamide: a valuable moiety to design new sulfa drug analogues

Romain Amador, Ali Tahrioui, Magalie Barreau, Olivier Lesouhaitier, Michael Smietana\* and Guillaume Clavé\*



1572

## Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs

Mengmeng Wang, Kunyu Qu, Peipei Zhao, Xin Yin, Yiwei Meng, Piet Herdewijn, Chao Liu,\* Lixin Zhang\* and Xuekui Xia\*

